In the News
FDA approves combination antibiotic for difficult-to-treat infections
The FDA approved the monobactam/beta-lactamase inhibitor combination for use in combination with metronidazole to treat patients who have limited or no treatment options for cIAIs caused by gram-negative bacteria, including Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae complex, Citrobacter freundii complex, and Serratia marcescens.
A breakthrough moment: McMaster researchers discover new class of antibiotics
A team led by renowned researcher Gerry Wright has identified a strong candidate to challenge even some of the most drug-resistant bacteria on the planet: a new class of antibiotics called lariocidin.
mRNA vaccines modified to include cytokine IL-12 enhance T cell response
The strong antibody responses generated by vaccines provide an important first round of defense, but "you always want to have a backup plan," says Biomedical Graduate Studies Ph.D. student Emily A. Aunins, considering viruses mutate to evade antibody responses that become widespread in a population. T cells, however, vary more between people and can still respond to reinfection and mutated viruses.
FDA approves powerful HIV prevention drug: What to know about Yeztugo
The twice-yearly injectable drug’s potential could be compromised by the Trump administration’s dramatic cuts to HIV-prevention infrastructure in the U.S.
U.S. FDA approves twice yearly shot to prevent HIV transmission
The Culture of Cure Award
The Culture of Cure Award is presented to an individual who exemplifies the core values and spirit of NTIDC through their daily actions, attitude, and commitment to excellence. This award honors someone who goes above and beyond in their role-not for recognition, but out of genuine dedication to their team, patients, and the mission of NTIDC.
Recipients of this award are team players who embody professionalism, integrity, compassion, and innovation. They contribute not only through their skills and work ethic, but also by uplifting those around them, embracing challenges with a positive mindset, and continually striving to improve systems, relationships, and outcomes.
This award celebrates the often unseen but deeply felt impact of those who help shape a culture of care, collaboration, and continuous improvement-driving the organization forward from the inside out.
Ultra-selective aptamers give viruses a taste of their own medicine
Inspired by the way viruses attach to cells, EPFL scientists have developed a method for engineering ultra-selective aptamers.
A big step toward an HIV cure?
New research in Nature Communications shows mRNA can reach resting T cells-key to targeting latent HIV. No harmful immune activation. Major potential.
Giving it a Try: A Guide to Clinical Trials
Studies of new treatments, prevention tools, comorbidity management and cure strategies are key to better quality of life for people living with or at risk for HIV.
Heart of Gold
This special issue, which highlights the latest in HIV treatment, takes a closer look at clinical trials.
Vaccination induces broadly neutralizing antibody precursors to HIV gp41
A key barrier to the development of vaccines that induce broadly neutralizing antibodies (bnAbs) against human immunodeficiency virus (HIV) and other viruses of high antigenic diversity is the design of priming immunogens that induce rare bnAb-precursor B cells.
Novel vaccine concept generates immune responses that could produce multiple types of HIV neutralizing antibodies
Transmission electron micrograph of HIV-1 virus particles (pink/tan) budding and replicating from a segment of a chronically infected H9 cell (teal).
Top 10 HIV Clinical Developments of 2023
It is inevitable that in a not-too-distant future, most people with HIV who live in richer nations will control their infection with medications that emerge from the end of a needle.
Are we winning the war on AIDS?
New HIV infection rates are falling, and treatments are improving. But do we have the political will to end HIV/AIDS?
Dallas Voice talked with Bryan King of North Texas Infectious Disease Consultants.
Lenacapavir for HIV-1 — Potential Promise of a Long-Acting Antiretroviral Drug
The Research Department at North Texas ID Consultants is proud to be listed in the New England Journal of Medicine as collaborators with this new, and exciting long acting antiretrovirals for the treatment of HIV. We are currently enrolling in other studies using long acting medications for the treatment of HIV. If you are interested in one of our clinical trials you can contact the research department through our website at www.infectiousdiseases.com under the research section.
You will need the Adobe Reader to view and print these documents. 